TABLE 5. Percentage of all patients according to duration of drug exposure during phase II and III clinical trial of FDA-approved antidepressantsa

Duration (days)

 537-18-8548

(n = 1173)

 534-30-9348

(n = 2171)

 537-19-9348

(n = 2256)

<14

100

100

100

14-30

86

82

86

31-90

66

77

71

91-182

34

38

23

183-365

19

31

12

>365

6

17

2

>720 <1 <2 >1

a Data is tabulated for three recently approved antidepressant agents, each is identified by a nine digit number used during the premarketing research. n = total number of patients who received the investigational drug during premarketing trials.

Back to Chapter

published 2000